Mersana Therapeutics Reports US FDA’s Partial Clinical Hold on New Patient Enrollment of UpRi for Platinum-Sensitive Ovarian Cancer
Shots:
- The US FDA has placed a partial clinical hold on new patient enrollment in the (UP-NEXT) and (UPGRADE-A) evaluating UpRi in patients with Pt-sensitive ovarian cancer
- The decision was based on the data which showed a higher rate of serious bleeding events in treated patients with Pt-resistant ovarian cancer & 5 cases of serious bleeding were fatal. Patients already enrolled can continue treatment
- The patient enrollment has been completed in the (UPLIFT) trial of UpRi for Pt-resistant ovarian cancer with results expected by early August. The company intends to work with the US FDA to lift the partial clinical hold and restart enrollment in (UP-NEXT) and (UPGRADE-A) trial
Ref: Globenewswire | Image: Mersana
Related News:- Merck Signs a Research Collaboration and Commercial License Agreement with Mersana for Novel Antibody-Drug Conjugates
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
